Calendar note: Today is Wednesday, August 5, 2026. CVS has confirmed its second-quarter results call for 8:00 a.m. ET today, so the event is today—not tomorrow. This preview is framed using information available ahead of the release. (investors.cvshealth.com)
CVS enters 2Q with a credible turnaround narrative already in the stock: better-than-expected Aetna execution, a first-quarter guidance increase, improving retail prescription momentum, and increasingly visible balance-sheet repair. The shares closed at $104.45 on August 4, up roughly 30% year to date based on available closing-price data.
That changes the burden of proof. A modest EPS beat alone may not be enough. Investors will likely focus on whether CVS can:
Third-party consensus data point to 2Q adjusted EPS of about $1.85, versus $1.81 in 2Q25. (tipranks.com) This is a relatively modest year-over-year hurdle, but the quality and durability of the result matter much more than the headline comparison.
After 1Q, CVS raised its 2026 adjusted EPS outlook to $7.30–$7.50, from $7.00–$7.20, and said it expected an approximately 60/40 split of annual earnings between the first and second halves. First-quarter adjusted EPS was $2.57. (cvshealth.com)
That math implies roughly:
| 2026 adjusted EPS guide | Implied 1H EPS at 60% | Less 1Q26 actual | Implied 2Q26 EPS |
|---|---|---|---|
| $7.30 | $4.38 | $2.57 | $1.81 |
| $7.50 | $4.50 | $2.57 | $1.93 |
Takeaway: the roughly $1.85 consensus estimate is broadly consistent with maintained guidance. Therefore, an EPS result around consensus accompanied by a confident full-year reaffirmation should be acceptable; a result materially above consensus with no uplift to guidance could invite questions about conservatism, timing, or second-half cost trends.
Aetna is still the central driver of the CVS equity story.
In 1Q, Health Care Benefits generated $3.04 billion of adjusted operating income, up 53% year over year, while the medical benefit ratio (MBR) improved 270 basis points to 84.6%. CVS attributed the result to better Government-business performance and the absence of the prior-year individual-exchange premium-deficiency reserve. It also reported $1.1 billion of favorable prior-year development. (cvshealth.com)
The important caveat is that management did not fully flow early core outperformance into its annual outlook; it retained a cautious view on medical-cost trends and maintained full-year MBR guidance of 90.5%, plus or minus 50 bps.
What is the 2Q MBR, and how much of the result comes from favorable prior-year development?
Investors want evidence that current-year medical-cost management—not reserve releases—is carrying the improvement.
Are medical-cost trends stable across Medicare Advantage, Medicaid, and Commercial?
Aetna’s Government businesses drove much of the 1Q improvement. Confirmation that Medicare Advantage pricing, benefit design, utilization management, and provider contracting are working would be the most consequential positive read-through.
Are reserves still adequate?
CVS’s 2Q25 result included a $471 million Group Medicare Advantage premium-deficiency reserve amid utilization pressure. That creates an easier comparison, but it also keeps reserve adequacy front and center. (cvshealth.com)
Does management maintain confidence in the path to target Medicare Advantage margins by 2028?
CVS has previously reiterated that objective. A reaffirmation matters; any qualification would likely outweigh a small quarterly EPS beat.
Bullish read: MBR and current-year utilization remain within expectations, prior-year development is not doing all the work, and Aetna’s 2026 operating-income outlook rises again.
Bearish read: a higher-than-expected MBR, more conservative reserve commentary, or evidence that pricing is lagging utilization—especially in Medicare Advantage.
The Health Services segment—principally Caremark/PBM, specialty, pharmacy services, and care delivery—was the main soft spot in 1Q. Adjusted operating income fell 7.1% year over year to $1.49 billion, reflecting pharmacy-client price improvements. Management also said that 1Q contained early recognition of value it had expected in 2Q, while underlying performance excluding that timing benefit modestly exceeded expectations. (cvshealth.com)
That makes 2Q inherently more difficult to read:
The regulatory backdrop also remains a valuation constraint. CVS continues to transition toward more transparent, net-cost PBM models, but state-level PBM rules and potential federal changes can pressure spreads, pharmacy reimbursement economics, and business-model complexity. CVS has said it has multiple pathways to its longer-term earnings targets, but 2Q commentary on the earnings impact and timing of regulatory change will matter.
Retail pharmacy has real operational momentum, but its earnings profile remains constrained by reimbursement pressure and investment.
In 1Q, Pharmacy & Consumer Wellness prescription volume rose 6.8%, with contributions from Rite Aid prescription-file acquisitions and broader utilization. Yet adjusted operating income declined 8.8% to $1.20 billion, as reimbursement pressure, investments, weather disruption, and lower seasonal-illness contribution more than offset volume. CVS nevertheless raised its full-year segment adjusted operating-income outlook to at least $6.18 billion. (cvshealth.com)
CVS’s 1Q guidance reset was meaningful:
The company ended 1Q with a leverage ratio of 3.84x and stressed that share repurchases were not embedded in 2026 guidance; the priority remained balance-sheet improvement. (cvshealth.com)
For 2Q, investors should focus on:
This would support the turnaround thesis, although the stock reaction could be muted if investors had positioned for another guidance increase.
CVS no longer needs to prove that the turnaround has started—it needs to prove that it is durable. The most important 2Q datapoint is not headline EPS; it is the quality of Aetna’s margin recovery and whether management can preserve or improve its 2026 outlook while absorbing PBM and pharmacy reimbursement pressure.
A clean 2Q would feature: disciplined MBR performance, stable reserves, no surprise in Health Services after the 1Q timing pull-forward, continued pharmacy-volume strength, and confident guidance commentary. If CVS delivers those elements, the company’s multiyear recovery narrative remains intact—though the share-price run means expectations are materially less forgiving than they were at the start of the year.